Judit Garcia-Villoria
Research group
- Inherited Metabolic Diseases and Muscular Disorders Accredited researcher (R3A)
Featured publications
-
Mutations in TIMM50 cause severe mitochondrial dysfunction by targeting key aspects of mitochondrial physiology.
Authors:Reference: Human Mutation 2019. -
FLAD1, encoding FAD synthase, is mutated in a patient with myopathy, scoliosis and cataracts
Authors:Reference: Clinical Genetics 2018. -
Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated ketoacid dehydrogenase complexes
Authors:Reference: Human Molecular Genetics 2014. -
Exome sequencing identifies a new mutation in SERAC1 in a patient with 3-methylglutaconic aciduria.
Authors:Reference: 2013. -
Improvement of the cystine measurement in granulocytes by liquid tandem mass spectrometry
Authors:Reference: Clinical Biochemistry 2013. -
X-inactivation of HSD17B10 revealed by cDNA analysis in two female patients with 17 beta-hydroxysteroid dehydrogenase 10 deficiency
Authors:Reference: European Journal Of Human Genetics 2010. -
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: an X-linked inborn error of isoleucine metabolism that may mimic a mitochondrial disease
Authors:Reference: Pediatric Research 2005.
Featured Projects
-
Identificación y caracterización de nuevos defectos del metabolismo energético mitocondrial asociados a aciduria 3 -metilglutacónica
Principal investigator: Antonia Ribes RubioFunder: Instituto de Salud Carlos IIICode: PI16/01048Duration: 01/01/2017 - 30/06/2020 -
An EU rare disease registry for Niemann-Pick disease type A, B and C
Principal investigator: Coll MJCode: 308901Duration: 01/01/2013 -
Estudios bioquímicos y mutacionales en pacientes con deficiencias primarias de CoQ. Selección bioquímica de pacientes y análisis de la vía metabólica mediante sustratos marcados con isótopos estables.
Funder: Fondo de Investigación SanitariaCode: PI08/0307.Duration: 31/12/2008 - 30/09/2012 -
06/CENIT: Estudio de proteínas vinculadas a la enfermedad de Alzheimer y a otros procesos neurodegenerativos. Implicaciones terapéuticas
Funder: Ministerio de Industria, Acrónimo: Nanofarma Contrato Nº / Referencia : 24 de Noviembre de 2005, Lipotec-Fundació Clínic Empresa/s que suscriben el contrato: Grupo Lipotec (BCN Peptides, GP Pharm, DiDuration: 01/01/2006